Essential Partners’s Inhibikase Therapeutics IKT Stock Holding History
Bought
Maintained
Sold
Other funds holding IKT
Essential Partners's IKT Position: Q3 2026 in Review
Essential Partners reduced its Inhibikase Therapeutics (IKT) stake by 35% in Q3 2026, selling an estimated $507 and leaving 423 shares worth $869. The position accounts for ﹤0.01% of the portfolio, ranked #2233.
Essential Partners first reported a position in IKT in Q1 2026 and has held it in 3 quarters since. The position peaked at $4.37K in Q1 2026. 8 funds tracked by Wall St. Rank hold IKT as of Q3 2026.
- Essential Partners held 423 shares of Inhibikase Therapeutics worth $869 as of Q3 2026.
- Essential Partners sold 223 Inhibikase Therapeutics shares in Q3 2026, an estimated $507.
- Inhibikase Therapeutics made up ﹤0.01% of Essential Partners's portfolio in Q3 2026, its #2233 holding.
- Essential Partners first reported a position in Inhibikase Therapeutics in Q1 2026 and has held it in 3 quarters since.
- Essential Partners's Inhibikase Therapeutics position peaked at $4.37K in Q1 2026.
- 8 funds tracked by Wall St. Rank held Inhibikase Therapeutics as of Q3 2026.
Based on Essential Partners's 13F filing for Q3 2026, filed 14 Oct 2026.